In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime

Cefepime is frequently prescribed to treat infections caused by AmpC-producing Gram-negative bacteria. CMY-2 is the most common plasmid-mediated AmpC (pAmpC) β-lactamase. Unfortunately, CMY variants conferring enhanced cefepime resistance have been reported. Here, we describe the evolution of CMY-2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Pires, João, Taracila, Magdalena, Bethel, Christopher R., Doi, Yohei, Kasraian, Sara, Tinguely, Regula, Sendi, Parham, Bonomo, Robert A., Endimiani, Andrea
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Mechanisms of Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4649241/
https://ncbi.nlm.nih.gov/pubmed/26392491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01804-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars